☆ 4.7 Meeting Abstract

Ponatinib in patients with acute myeloid leukemia (AML): Preliminary findings from a phase I study in hematologic malignancies

JOURNAL OF CLINICAL ONCOLOGY (2011)

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 29, Issue 15, Pages -

Publisher

AMER SOC CLINICAL ONCOLOGY

DOI: 10.1200/jco.2011.29.15_suppl.6518

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Oncology

PET-CT in Clinical Adult Oncology: I. Hematologic Malignancies

Ahmed Ebada Salem, Harsh R. Shah, Matthew F. Covington, Bhasker R. Koppula, Gabriel C. Fine, Richard H. Wiggins, John M. Hoffman, Kathryn A. Morton

Summary: This article discusses the applications of PET-CT in hematologic malignancies, including an outline of the classification, critical applications, and imaging features. It serves as a practical guide for healthcare professionals in the clinical management of adult patients with hematologic malignancies.

CANCERS (2022)

Add to Collection

Article Pharmacology & Pharmacy

TBC1D16 predicts chemosensitivity and prognosis in adult acute myeloid leukemia (AML) patients

Han Liu, Peng Chen, Yong-Long Yang, Ke-Wei Zhu, Tao Wang, Ling Tang, Yan-Ling Liu, Shan Cao, Gan Zhou, Hui Zeng, Xie-Lan Zhao, Wei Zhang, Xiao-Ping Chen

Summary: The study identified TBC1D16 as a potential predictor for chemosensitivity and prognosis in adult AML patients, with higher methylation and expression of this gene associated with increased risk of incomplete remission and worse overall survival.

EUROPEAN JOURNAL OF PHARMACOLOGY (2021)

Add to Collection

Article Oncology

Context-specific effects of NOX4 inactivation in acute myeloid leukemia (AML)

Muhammed Burak Demircan, Tina M. Schnoeder, Peter C. Mgbecheta, Katrin Schroeder, Frank-D Boehmer, Florian H. Heidel

Summary: Oxidative stress has been found to be associated with cancer initiation and progression. Recent studies have shown the potential therapeutic role of ROS modulation in various cancers, including acute myeloid leukemia (AML). A detailed understanding of the complex machinery regulating ROS in cancer is essential for defining potential therapeutic applications.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Clinical insights into hematologic malignancies and comparative analysis of molecular signatures of acute myeloid leukemia in different ethnicities using an artificial intelligence offering

Jane L. Snowdon, Dilhan Weeraratne, Hu Huang, David Brotman, Shang Xue, Van C. Willis, Young Kyung Lee, Kibum Jeon, Dae Young Zang, Hyo Jung Kim, Ho Young Kim, Boram Han, Miyoung Kim

Summary: This study evaluated the performance of artificial intelligence-based Watson for Genomics in hematologic malignancies, finding it to provide useful information in diagnosis, prognosis, and treatment. Variant interpretation using WfG correlated well with manually curated expert opinions and provided unique insights into targeted drugs and clinical trials.

MEDICINE (2021)

Add to Collection

Article Oncology

Psychological mobile app for patients with acute myeloid leukemia (AML): A pilot randomized clinical trial

Areej El-Jawahri, Marlise R. Luskin, Joseph A. Greer, Lara Traeger, Mitchell Lavoie, Dagny Marie Vaughn, Stephanie Andrews, Daniel Yang, Kofi Y. Boateng, Richard A. Newcomb, Nneka N. Ufere, Amir T. Fathi, Gabriela Hobbs, Andrew Brunner, Gregory A. Abel, Richard M. Stone, Daniel J. DeAngelo, Martha Wadleigh, Jennifer S. Temel

Summary: A psychological mobile application called DREAMLAND was developed for patients with newly diagnosed AML who are receiving intensive chemotherapy. The app consists of four modules aimed at improving patient-reported outcomes during treatment. Results showed that patients who used DREAMLAND reported improved quality of life, mood, symptom burden, and self-efficacy compared to the usual care group.

CANCER (2023)

Add to Collection

Review Medicine, Research & Experimental

Role of Acute Myeloid Leukemia (AML)-Derived exosomes in tumor progression and survival

Ali H. Amin, Liqaa Mohammed Al Sharifi, Alisher Jamoliddinovich Kakhharov, Maria Jade Catalan Opulencia, Fahad Alsaikhan, Dmitry Olegovich Bokov, Hasan Sh Majdi, Mohammed Abed Jawad, Ali Thaeer Hammid, Mohammed Nader Shalaby, Yasser Fakri Mustafa, Homayoon Siahmansouri

Summary: Acute myeloid leukemia (AML) is an aggressive hematopoietic disorder characterized by the accumulation and clonal expansion of immature myeloid cells. Repeated relapses and drug resistance pose major challenges in treatment, and the tumor microenvironment plays a critical role in these treatment failures. Exosomes, membrane-bound extracellular vesicles, are known to transfer signaling molecules and contribute to inter-cellular communication. In AML, exosomes derived from bone marrow mesenchymal stem cells (BMSCs) and AML cells themselves play a significant role in the proliferation and progression of leukemia.

BIOMEDICINE & PHARMACOTHERAPY (2022)

Add to Collection

Article Cell Biology

Integrated N- and O-Glycomics of Acute Myeloid Leukemia (AML) Cell Lines

Constantin Blochl, Di Wang, Katarina Madunic, Guinevere S. M. Lageveen-Kammeijer, Christian G. Huber, Manfred Wuhrer, Tao Zhang

Summary: AML presents challenges in treatment due to high rates of relapse or refractory disease. Recent studies have highlighted the importance of protein glycosylation in AML pathobiology, with specific glycan epitopes linked to disease outcome. This exploratory glycomics study identified distinct glycan structures in AML cell lines, providing insights into potential drivers of glycan phenotype.

CELLS (2021)

Add to Collection

Review Hematology

BCL2 and MCL1 inhibitors for hematologic malignancies

Andrew W. Roberts, Andrew H. Wei, David C. S. Huang

Summary: BH3 mimetics are a new class of anticancer drugs that target prosurvival BCL2 proteins to induce apoptosis, with Venetoclax being the first approved BCL2 inhibitor showing activity in various lymphoid and myeloid neoplasms. Long-term exposure may lead to secondary resistance. Success of BCL2 inhibitors has led to development of BH3 mimetics targeting MCL1, with promising preclinical activity but potential challenges due to MCL1's physiological roles in nonhematologic tissues.

BLOOD (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Immunotherapy in hematologic malignancies: achievements, challenges and future prospects

Lu Tang, Zhongpei Huang, Heng Mei, Yu Hu

Summary: The immune-cell origin of hematologic malignancies has contributed to accelerated progress in immunotherapy by providing insights into immune responsiveness and escape mechanisms. Different categories of immunotherapies, such as stem cell transplantation and immune checkpoint inhibitors, have shown potential for long-term remission in blood cancers. However, these approaches also have shortcomings that need to be addressed. A comprehensive review provides clinicians with historical perspectives, recent advances, mechanisms of action, clinical trials and outcomes, adverse effects and toxicity management, as well as challenges and future directions in immunotherapy for hematologic malignancies.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2023)

Add to Collection

Article Oncology

Adenosine Monophosphate Activated Protein Kinase (AMPK) enhances chemotherapy response in Acute Myeloid Leukemia (AML)

Lais Ghiraldeli, Rebecca Anderson, Kristin Pladna, Timothy S. Pardee

Summary: Adenosine monophosphate activated protein kinase (AMPK) plays an important role in chemotherapy response in acute myeloid leukemia (AML). Knocking out AMPK activity in AML cells results in significant resistance to chemotherapy drugs and is associated with shorter survival in patients with low expression of AMPK subunit. Additionally, sensitizing AML cells to chemotherapy can be achieved by activating AMPK.

CANCER LETTERS (2022)

Add to Collection

Article Oncology

Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG

Mareike Rasche, Martin Zimmermann, Emma Steidel, Todd Alonzo, Richard Aplenc, Jean-Pierre Bourquin, Heidrun Boztug, Todd Cooper, Alan S. Gamis, Robert B. Gerbing, Iveta Janotova, Jan-Henning Klusmann, Thomas Lehrnbecher, Nora Muehlegger, Nils V. Neuhoff, Naghmeh Niktoreh, Lucie Sramkova, Jan Stary, Katharina Waack, Christiane Walter, Ursula Creutzig, Michael Dworzak, Gertjan Kaspers, Edward Anders Kolb, Dirk Reinhardt

Summary: This study evaluated survival, response, and prognostic variables following relapse in children with acute myeloid leukemia (AML). Initial high-risk features and early relapse were found to predict post-relapse survival, while full hematopoietic recovery did not necessarily correlate with better survival outcomes. The data suggest the need for post-relapse risk stratification in future studies.

CANCERS (2021)

Add to Collection

Article Oncology

Posttraumatic stress disorder (PTSD) symptoms in patients with acute myeloid leukemia (AML)

Hermioni L. Amonoo, Thomas W. LeBlanc, Alison R. Kavanaugh, Jason A. Webb, Lara N. Traeger, Annemarie D. Jagielo, Dagny M. Vaughn, Madeleine Elyze, Regina M. Longley, Amir T. Fathi, Gabriela S. Hobbs, Andrew M. Brunner, Nina R. O'Connor, Selina M. Luger, Jillian L. Gustin, Bhavana Bhatnagar, Nora K. Horick, Areej El-Jawahri

Summary: A substantial proportion of AML patients report clinically significant PTSD symptoms 1 month after initiating intensive chemotherapy, with baseline QOL, coping strategies, and the extent of QOL decline during hospitalization emerging as important risk factors for PTSD.

CANCER (2021)

Add to Collection

Editorial Material Cell & Tissue Engineering

SEPHguarding acute myeloid leukemia

Malini Gupta, Britta Will

Summary: Adaptive aberrant gene regulation is a hallmark of malignant growth and therapy resistance in acute myeloid leukemia (AML). In this study, Eagle et al. identified oncogenic enhancer-driven overexpression of selenophosphate synthetase 2 (SEPHS2) as a targeted opportunity for mitigating malignant cell growth in AML.

CELL STEM CELL (2022)

Add to Collection

Review Cell Biology

Role of Notch Receptors in Hematologic Malignancies

Laura Gragnani, Serena Lorini, Silvia Marri, Anna Linda Zignego

Summary: Notch receptors play critical roles in fundamental cellular processes and are implicated in hematopoiesis, angiogenesis, and various human malignancies. They could serve as potential therapeutic targets for hematological cancers.

CELLS (2021)

Add to Collection

Article Oncology

Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

Stephen M. Ansell, Michael B. Maris, Alexander M. Lesokhin, Robert W. Chen, Ian W. Flinn, Ahmed Sawas, Mark D. Minden, Diego Villa, Mary-Elizabeth M. Percival, Anjali S. Advani, James M. Foran, Steven M. Horwitz, Matthew G. Mei, Jasmine Zain, Kerry J. Savage, Christiane Querfeld, Oleg E. Akilov, Lisa D. S. Johnson, Tina Catalano, Penka S. Petrova, Robert A. Uger, Eric L. Sievers, Anca Milea, Kathleen Roberge, Yaping Shou, Owen A. O'Connor

Summary: The study evaluated the safety and activity of TTI-621 in relapsed/refractory hematologic malignancies, indicating that TTI-621 demonstrated certain therapeutic effects and good tolerability overall in patients.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Oncology

Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

Andreas Hochhaus, Delphine Rea, Carla Boquimpani, Yosuke Minami, Jorge E. Cortes, Timothy P. Hughes, Jane F. Apperley, Elza Lomaia, Sergey Voloshin, Anna Turkina, Dong-Wook Kim, Andre Abdo, Laura Maria Fogliatto, Philipp le Coutre, Koji Sasaki, Dennis Dong Hwan Kim, Susanne Saussele, Mario Annunziata, Naeem Chaudhri, Lynette Chee, Valentin Garcia-Gutierrez, Shruti Kapoor, Alex Allepuz, Sara Quenet, Veronique Bedoucha, Michael J. Mauro

Summary: Asciminib, a BCR-ABL1 inhibitor that targets the ABL Myristoyl Pocket (STAMP), is approved worldwide for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (CML-CP) who have been previously treated with at least 2 tyrosine kinase inhibitors (TKIs). In the ASCEMBL study, asciminib demonstrated superior efficacy and better safety and tolerability compared to bosutinib in patients with CML-CP who had received at least 2 prior TKIs. The major molecular response rate at week 96 was significantly higher with asciminib than with bosutinib, and fewer adverse events and treatment discontinuations were observed with asciminib.

LEUKEMIA (2023)

Add to Collection

Article Hematology

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial

Justin M. Watts, Maria R. Baer, Jay Yang, Thomas Prebet, Sangmin Lee, Gary J. Schiller, Shira N. Dinner, Arnaud Pigneux, Pau Montesinos, Eunice S. Wang, Karen P. Seiter, Andrew H. Wei, Stephane De Botton, Montserrat Arnan, Will Donnellan, Anthony P. Schwarer, Christian Recher, Brian A. Jonas, P. Brent Ferrell Jr, Christophe Marzac, Patrick Kelly, Jennifer Sweeney, Sanjeev Forsyth, Sylvie M. Guichard, Julie Brevard, Patrick Henrick, Hesham Mohamed, Jorge E. Cortes

Summary: This study evaluated the safety, pharmacokinetics, pharmacodynamics, and clinical activity of Olutasidenib in patients with acute myeloid leukemia or myelodysplastic syndrome with mutant IDH1. The results showed that Olutasidenib, as monotherapy or in combination with azacitidine, was well tolerated and exhibited meaningful clinical activity. These findings provide a rationale for further evaluation of Olutasidenib in different populations of patients with myeloid malignancies.

LANCET HAEMATOLOGY (2023)

Add to Collection

Review Cardiac & Cardiovascular Systems

Cardiovascular Toxicities Associated with Tyrosine Kinase Inhibitors

Nicolas Sayegh, Juliet Yirerong, Neeraj Agarwal, Daniel Addison, Michael Fradley, Jorge Cortes, Neal L. Weintraub, Nazish Sayed, Girindra Raval, Avirup Guha

Summary: The purpose of this review is to provide a detailed overview of the cardiovascular adverse events associated with the use of tyrosine kinase inhibitors in different types of tumors. Recent findings have shown that while tyrosine kinase inhibitors have a survival advantage, they can also cause life-threatening cardiovascular adverse events. Different tyrosine kinase inhibitors have varying cardiovascular toxic profiles, with imatinib possibly being cardioprotective. Vascular endothelial growth factor tyrosine kinase inhibitors are strongly associated with hypertension and arterial ischemic events in the treatment of solid tumors.

CURRENT CARDIOLOGY REPORTS (2023)

Add to Collection

Article Oncology

Clinical Utility of Optical Genome Mapping and 523-Gene Next Generation Sequencing Panel for Comprehensive Evaluation of Myeloid Cancers

Nikhil Shri Sahajpal, Ashis K. Mondal, Harmanpreet Singh, Ashutosh Vashisht, Sudha Ananth, Daniel Saul, Alex R. Hastie, Benjamin Hilton, Barbara R. DuPont, Natasha M. Savage, Vamsi Kota, Alka Chaubey, Jorge E. Cortes, Ravindra Kolhe

Summary: The current genetic testing of myeloid cancers lacks resolution and is limited to specific genomic regions/genes. This study used a combination of high-resolution cytogenetic technology and next-generation sequencing to obtain a comprehensive genomic profile of these tumors. The combinatorial approach identified new genetic alterations and clinically relevant alterations in previously negative cases.

CANCERS (2023)

Add to Collection

Article Oncology

Population modeling of bosutinib exposure-response in patients with newly diagnosed chronic phase chronic myeloid leukemia

May Garrett, Beverly Knight, Jorge E. Cortes, Michael W. Deininger

Summary: This study compared the impact of different doses of bosutinib on the efficacy and safety outcomes of patients with chronic phase chronic myeloid leukemia. The results showed that a starting dose of 400 mg QD had better tolerability and did not compromise efficacy compared to a dose of 500 mg QD.

CANCER MEDICINE (2023)

Add to Collection

Article Economics

Health care resource utilization in 3L+patients with chronic phase chronic myeloid leukemia receiving asciminib or bosutinib

Jorge E. Cortes, Delphine Rea, Michael J. Mauro, Diana Tran, Pearl Wang, Kejal Jadhav, Aurore Yocolly, Koji Sasaki

Summary: This study assessed and compared the health care resource utilization (HCRU) rates of asciminib and bosutinib among 3 L+ patients with chronic myeloid leukemia in chronic phase (CML-CP) in the ASCEMBL trial. The results showed that asciminib-treated patients had lower resource utilization compared to bosutinib-treated patients over the long-term.

JOURNAL OF MEDICAL ECONOMICS (2023)

Add to Collection

Review Hematology

Disparities in survival of hematologic malignancies in the context of social determinants of health: a systematic review

Marisol Miranda-Galvis, Kellen C. Tjioe, E. Andrew Balas, Gagan Agrawal, Jorge E. Cortes

Summary: This article evaluates the impact of social determinants of health on the outcomes of patients with hematologic malignancies. The study found that factors such as education level, health insurance coverage, income level, and marital status significantly affect patients' survival rates. However, there are contradictory reports regarding the effect of distance to treatment centers on treatment outcomes. Additionally, data on transportation, debt, diet, and other factors are lacking.

BLOOD ADVANCES (2023)

Add to Collection

Meeting Abstract Oncology

Responses With Asciminib Continue to Deepen Over Time in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase III ASCEMBL Study

Michael Mauro, Andreas Hochhaus, Timothy Hughes, Delphine Rea, Carla Boquimpani, Yosuke Minami, Jane Apperley, Valentin Garcia-Gutierrez, Shruti Kapoor, Noemi Espurz, Vishal Dhamal, Jorge Cortes

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023)

Add to Collection

Meeting Abstract Oncology

Cancer Disparities in Survival of Patients With Hematologic Malignancies in the Context of Social Determinants of Health: A Systematic Review

Marisol Miranda-Galvis, Kellen Tjioe, Andrew Balas, Gagan Agrawal, Jorge Cortes

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023)

Add to Collection

Meeting Abstract Oncology

Early Cytogenetic or Molecular Landmark Response to Ponatinib Treatment Predicts Outcomes in Heavily Pretreated Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in PACE: 5-Year Data

Martin C. Mueller, Jorge Cortes, Charles Chuah, Daniel J. DeAngelo, Michael Deininger, Francois Guilhot, Timothy Hughes, Franck E. Nicolini, Javier Pinilla-Ibarz, Delphine Rea, Gianantonio Rosti, Neil P. Shah, Moshe Talpaz, Vickie Lu, Thihan Padukkavidana, Hagop M. Kantarjian

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023)

Add to Collection

Meeting Abstract Oncology

Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Patients With Treatment-Resistant Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Treated With Ponatinib From the Phase 2 OPTIC Trial

Jane Apperley, Jorge Cortes, Elias Jabbour, Andreas Hochhaus, Timothy Hughes, Charles Chuah, Hugues de Lavallade, Michael Deininger, Jeffrey H. Lipton, Elza Lomaia, Lori Maness, Michael Mauro, James McCloskey, Beatriz Moiraghi, Carolina Pavlovsky, Christine Rojas, Philippe Rousselot, Tomasz Sacha, Moshe Talpaz, Anna Turkina, Maria Undurraga Sutton, Xiaowei Ren, Alexander Vorog, Gianantonio Rosti

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023)

Add to Collection

Meeting Abstract Oncology

ASC2ESCALATE: A US, Phase II Open-Label, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Second-Line (2L) and First-Line (1L) Treatment of Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Ehab Atallah, Michael Mauro, Koji Sasaki, Moshe Levy, Paul Koller, Daisy Yang, Dramane Laine, John Sabo, Ennan Gu, Jorge Cortes

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023)

Add to Collection

Meeting Abstract Oncology

T-Cell Exhaustion and Immune Checkpoint VISTA Overexpression Are Associated With Suboptimal Response to Tyrosine Kinase Inhibitors (TKIs) in Patients With Chronic Myeloid Leukemia (CML)

Aram Bidikian, Sreyashi Basu, Zhong He, Himachandana Atluri, Jabra Zarka, Michael Andreeff, Koji Sasaki, Elias Jabbour, Jorge E. Cortes, Padmanee Sharma, Ghayas C. Issa

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023)

Add to Collection

Meeting Abstract Oncology

The Importance of Quality of Survivorship: US Results From the Chronic Myeloid Leukemia (CML) Survey on Unmet Needs (SUN)

Joannie Clements, Cristina Ruiz, Andrea Damon, Peter Schuld, Pauline Frank, Cristina Constantinescu, Jorge Cortes

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023)

Add to Collection

Meeting Abstract Oncology

Post Hoc Analysis of Patient Responses by T315I Mutation Status From the 3-Year Update of the OPTIC Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Jorge Cortes, Michael Deininger, Elza Lomaia, Beatriz Moiraghi, Maria Undurraga Sutton, Carolina Pavlovsky, Charles Chuah, Tomasz Sacha, Jeffrey H. Lipton, James McCloskey, Philippe Rousselot, Gianantonio Rosti, Hugues de Lavallade, Christine Rojas, Anna Turkina, Moshe Talpaz, Michael Mauro, Vickie Lu, Alexander Vorog, Jane Apperley

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.